Literature DB >> 20882136

Preventing bone complications in advanced prostate cancer.

M A Luz1, A G Aprikian.   

Abstract

The diagnosis and treatment of prostate cancer have steadily been improving since the late 1980s. However, clinicians still confront a large group of men developing disease metastatic to bone. Adequate control of bone complications plays a fundamental role in achieving control of symptoms and quality of life in this group. Androgen deprivation therapy, the standard treatment for advanced prostate cancer, increases the risk of various complications, including bone disease. This review addresses the prevention of bone complications related not only to prostate cancer metastases but also to impaired bone integrity caused by androgen deprivation therapy.

Entities:  

Keywords:  Prostate cancer; bone metastases; skeletal complications

Year:  2010        PMID: 20882136      PMCID: PMC2935713          DOI: 10.3747/co.v17i0.722

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  49 in total

Review 1.  Bone health and prostate cancer.

Authors:  P J Saylor; M R Smith
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-11-10       Impact factor: 5.554

2.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

3.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

4.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 5.  Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.

Authors:  J R Ross; Y Saunders; P M Edmonds; S Patel; K E Broadley; S R D Johnston
Journal:  BMJ       Date:  2003-08-30

6.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Authors:  M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

7.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

Authors:  David P Dearnaley; Matthew R Sydes; Malcolm D Mason; Mark Stott; Christopher S Powell; Anne C R Robinson; Peter M Thompson; Leslie E Moffat; Sharon L Naylor; Mahesh K B Parmar
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506

Review 8.  New bisphosphonates in the treatment of bone metastases.

Authors:  S D Averbuch
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

Review 9.  Pathogenesis of osteoblastic bone metastases from prostate cancer.

Authors:  Toni Ibrahim; Emanuela Flamini; Laura Mercatali; Emanuele Sacanna; Patrizia Serra; Dino Amadori
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

10.  Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.

Authors:  Abbas H Panju; Henriette Breunis; Angela M Cheung; Marc Leach; Neil Fleshner; Padraig Warde; Sarah Duff-Canning; Murray Krahn; Gary Naglie; Ian Tannock; George Tomlinson; Shabbir M H Alibhai
Journal:  BJU Int       Date:  2008-10-24       Impact factor: 5.588

View more
  2 in total

1.  Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis.

Authors:  Louise Perrault; Vincent Fradet; Véronique Lauzon; Jacques LeLorier; Dominic Mitchell; Mohdhar Habib
Journal:  Can Urol Assoc J       Date:  2015 Sep-Oct       Impact factor: 1.862

2.  Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.

Authors:  Esmail M Al-Ezzi; Husam A Alqaisi; Marco A J Iafolla; Lisa Wang; Srikala S Sridhar; Adrian G Sacher; Nazanin Fallah-Rad; Di M Jiang; Geoffrey A Watson; Charles N Catton; Padraig R Warde; Rob J Hamilton; Neil E Fleshner; Alexandre R Zlotta; Aaron R Hansen
Journal:  Cancer Med       Date:  2021-07-13       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.